LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Purchased by Sei Investments Co.

Sei Investments Co. lifted its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 9.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,857 shares of the medical instruments supplier’s stock after purchasing an additional 8,494 shares during the period. Sei Investments Co. owned about 0.43% of LeMaitre Vascular worth $8,924,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Copeland Capital Management LLC raised its stake in shares of LeMaitre Vascular by 0.7% during the 4th quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier’s stock worth $107,990,000 after buying an additional 8,623 shares during the period. State Street Corp increased its holdings in LeMaitre Vascular by 3.6% in the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock worth $76,363,000 after acquiring an additional 28,525 shares in the last quarter. Congress Asset Management Co. raised its position in LeMaitre Vascular by 1.8% during the fourth quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier’s stock worth $66,555,000 after acquiring an additional 13,009 shares during the period. Geode Capital Management LLC lifted its holdings in LeMaitre Vascular by 4.5% during the third quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier’s stock valued at $50,403,000 after purchasing an additional 23,443 shares in the last quarter. Finally, DF Dent & Co. Inc. grew its position in shares of LeMaitre Vascular by 26.2% in the third quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock valued at $24,037,000 after purchasing an additional 53,797 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $83.05 on Monday. The company has a market capitalization of $1.87 billion, a P/E ratio of 45.38, a P/E/G ratio of 2.22 and a beta of 0.89. The company has a 50 day simple moving average of $93.07 and a 200-day simple moving average of $94.42. LeMaitre Vascular, Inc. has a 1 year low of $62.39 and a 1 year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.49. The company had revenue of $55.81 million during the quarter, compared to analysts’ expectations of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.96%. The ex-dividend date of this dividend was Thursday, March 13th. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio (DPR) is 41.24%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LMAT. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price target for the company. Oppenheimer downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Lake Street Capital lifted their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Five analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $95.25.

Insider Activity

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares of the company’s stock, valued at $456,915.68. The trade was a 26.53 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.